2-Deoxyglucose Enhances the Chemosensitivity of B16-F10 Melanoma Cells to Cisplatin

• Main Authors: Jhuan-Yi Liou, 劉顓毅
• Other Authors: Ming-Hong Tai
• Format: Others
• Language: en_US
• Published: 2013
• Online Access: http://ndltd.ncl.edu.tw/handle/19856985957476115143

碩士 === 國立中山大學 === 生物醫學研究所 === 101 === Although cisplatin is among the most potent antitumor agents, cisplatin-based chemotherapy has shown limited effectiveness for treating melanoma. Our previous work showed that cisplatin induces chemoresistance in melanoma by elevating cancer stemness marker ABCB5, which indicates the involvement of chemoresistance mechanisms in the ATP synthesis pathway. Specifically, cisplatin treatment increases production of mitochondria and ATP in melanoma. The glucose analog 2-deoxyglucose (2-DG), which is a glycolytic inhibitor, decreases cellular ATP. Specifically, 2-DG attenuates the elevation of cellular ATP caused by cisplatin in B16-F10 melanoma cells. After cisplatin treatment, 2-DG also reduces cellular levels of ABCB5. Moreover, 2-DG enhances the inhibitory effect of cisplatin on anchorage-independent growth of B16-F10 melanoma cells. Invasion assays further show that a combined treatment with 2-DG (2 mM) and cisplatin (3 μM) has a larger attenuating effect on the invasiveness of B16-F10 melanoma cells compared to 2-DG alone or cisplatin alone. In conclusion, treatment combining the glycolytic inhibitor 2-DG with cisplatin may have potent applications in melanoma therapy.